Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| AC IMMUNE | 9 | - | +12,39 % | ||
| RHYTHM PHARMACEUTICALS | 8 | 3 | -1,00 % | ||
| BIONTECH | 7 | 13 | +0,92 % | ||
| KYMERA THERAPEUTICS | 7 | 6 | 0,00 % | ||
| MODERNA | 6 | 16 | 0,00 % | ||
| AMGEN | 4 | 27 | +0,80 % | ||
| ALNYLAM PHARMACEUTICALS | 4 | 9 | -0,09 % | ||
| AVADEL PHARMACEUTICALS | 4 | 6 | +0,55 % | ||
| ROIVANT SCIENCES | 4 | 3 | +1,18 % | ||
| GERON | 4 | - | -0,42 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08:30 | Morgen-Update: Biontech-Aktie stabil - Marktbeobachter rechnen mit Bewegung. | Hebelschein-Spekulant | |||
| 08:29 | Genmab Meets Conditions For $97/shr Merus Tender Offer | 6 | RTTNews | ||
| 08:10 | Jefferies startet Coverage für Moderna mit "Halten" und Kursziel von 30 US-Dollar | 3 | Investing.com Deutsch | ||
| 07:54 | Jefferies initiates Moderna stock with Hold rating, $30 price target | 3 | Investing.com | ||
| 07:42 | Genmab A/S: Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period | 150 | Business Wire | Company Announcement Transaction adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab's portfolio Transaction anticipated to be accretive to Genmab's... ► Artikel lesen | |
| 04:30 | Amgen CDR (CAD Hedged): Amgen CDR (CAD Hedged) estimates dividend | 4 | Stockwatch | ||
| 03:42 | FDA Approves Amgen's UPLIZNA For Adults With Generalized Myasthenia Gravis | 263 | AFX News | THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) announced that the U.S. Food and Drug Administration has approved UPLIZNA (inebilizumab-cdon) for the treatment of generalized myasthenia gravis (gMG)... ► Artikel lesen | |
| 00:30 | FDA approves Amgen's UPLIZNA for generalized myasthenia gravis | 5 | Investing.com | ||
| 00:30 | Mesoblast Limited: Independent Study Presented at American Society of Hematology (ASH) Annual Meeting Concludes Remestemcel-L Superior to Ruxolitinib in Clinical Outcomes as Treatment for SR-aGvHD | 2 | GlobeNewswire (USA) | ||
| 00:24 | Cycle Pharmaceuticals acquiring Applied Therapeutics | 12 | Seeking Alpha | ||
| 00:02 | MESOBLAST LIMITED: Study at ASH Concludes Remestemcel-L Superiority in SR-aGvHD | 2 | ASX | ||
| Do | Terns Pharmaceuticals nimmt 747,5 Millionen US-Dollar durch öffentliche Platzierung ein | 1 | Investing.com Deutsch | ||
| Do | Cycle Pharmaceuticals to Acquire Applied Therapeutics | 9 | GlobeNewswire (Europe) | NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT; "Applied"), a clinical-stage biopharmaceutical company dedicated to creating transformative treatments for rare... ► Artikel lesen | |
| Do | Raymond James initiates Phathom Pharmaceuticals stock with Strong Buy rating | 3 | Investing.com | ||
| Do | Oruka Therapeutics appoints Chris Martin to board of directors | 1 | Investing.com | ||
| Do | Structure Therapeutics closes $747.5 million public offering | 1 | Investing.com | ||
| Do | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares | 2 | GlobeNewswire (Europe) | WALTHAM, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven... ► Artikel lesen | |
| Do | Terns Pharmaceuticals, Inc.: Terns Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares | 3 | GlobeNewswire (Europe) | FOSTER CITY, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (Nasdaq: TERN), a clinical-stage oncology company, today announced the closing of its... ► Artikel lesen | |
| Do | Crinetics Pharmaceuticals, Inc.: Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) | 264 | GlobeNewswire (Europe) | Phase 3 study builds on positive phase 2 results showing rapid and sustained reductions in key disease biomarkers and clinical measures of CAHSAN DIEGO, Dec. 11, 2025(Nasdaq: CRNX) today announced that... ► Artikel lesen | |
| Do | Oruka Therapeutics, Inc.: Oruka Therapeutics Announces New Board Member and Board Transition | 1 | GlobeNewswire (USA) |
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .